CDx Diagnostics to Highlight Groundbreaking New WATS3D Data at the American College of Gastroenterology Annual Scientific Meeting

First Study Evaluating the WATS3D Biopsy for the Detection of Biliary Tract Cancer

Two Studies Reinforcing the Value of WATS3D for Surveillance of Esophageal Pre-Cancer

SUFFERN, NY–(Marketwired – Oct 10, 2013) – CDx Diagnostics today announced that important new WATS3D (Wide Area Transepithelial Sample) clinical data will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course, taking place from October 11-16, 2013 in San Diego. New WATS3D studies and scientific presentations at the meeting include:

The first study evaluating WATS3D for detecting cancer of the biliary tract
Two studies that add to the large evidence base supporting using WATS3D to monitor patients who have received ablation therapy for esophageal pre-cancer
A hands-on workshop presentation that will provide an overview of the WATS3D technology
The WATS3D biopsy collects a wide area, disaggregated tissue specimen of the entire thickness of the suspect epithelium. This unique tissue specimen is then subjected to specialized, computer-assisted 3-dimensional analysis to pinpoint potentially abnormal cells for presentation to a pathologist. In clinical trials, adjunctive use of WATS3D significantly increased the detection rate of both Barrett’s esophagus and esophageal dysplasia. ACG attendees can visit booth # 331 to learn more about WATS3D.

“Early detection is the key to preventing cancers of the esophagus and biliary tract, but the current diagnostic tools available to gastroenterologists have serious limitations,” said Mark Rutenberg, Chairman and CEO of CDx Diagnostics. “WATS3D addresses this urgent unmet need by enhancing the detection of pre-cancer missed by standard methods. Since the product was introduced last year, we have seen rapid uptake and the new data being presented at ACG should help to educate the gastroenterology community about the benefits of integrating WATS3D into clinical practice.”

Poster P1198: “Wide-area Transepithelial Sampling (WATS3D) Brush Biopsy as an Adjunct to Forceps Biopsy for the Detection of Barrett’s Metaplasia and Dysplasia after Endoscopic Therapy”
Danielle Marino, MD, Donald N. Tsynman, MD, Vivek Kaul, MD, University of Rochester Medical CenterAbout CDx Diagnostics and the WATS3D Biopsy
CDx Diagnostics’ mission is to provide doctors with the most powerful diagnostic technology to help prevent cancer before it can start.

CDx Diagnostics’ WATS3D biopsy addresses the sampling error inherent in random forceps biopsy testing of the esophagus. In just a few minutes, gastroenterologists can easily obtain a wide area, full-thickness transepithelial tissue sample for computer-assisted 3D laboratory analysis. In clinical trials, adjunctive use of CDx Diagnostics’ WATS3D biopsy significantly increased the detection rate of both Barrett’s esophagus and esophageal dysplasia. The high sensitivity of WATS3D is due to the large tissue area sampled, and the proprietary 3-Dimensionial computer imaging system that is based on an algorithm developed as part of the U.S. Strategic Defense Initiative missile defense program. To learn more about WATS3D, visit www.cdxdiagnostics.com.